What is Abrocitinib?
Abrocitinib is a medication used to treat moderate-to-severe atopic dermatitis. It works by selectively inhibiting Janus kinase 1 (JAK1), an enzyme involved in the signaling pathways of inflammatory cytokines [1].
What does US Patent 9035074 cover for Abrocitinib?
U.S. Patent 9,035,074 is one of several patents related to abrocitinib. This patent specifically describes methods of treating atopic dermatitis with abrocitinib [2]. Patent information, including details on patents like US9035074 and their expiration dates, can be found on DrugPatentWatch.com [3].
When does Abrocitinib's patent exclusivity expire?
The patent landscape for abrocitinib is complex, with multiple patents covering the drug and its uses. Expiration dates vary for different patents. Information on abrocitinib's patent expiry and market exclusivity can be accessed through resources like DrugPatentWatch.com [3].
What are the potential risks or side effects of Abrocitinib?
As with many medications, abrocitinib carries potential risks and side effects. Common side effects may include nausea, headache, and nasopharyngitis. More serious risks, such as infections, blood clots, or certain types of cancer, have also been associated with JAK inhibitors [1]. Patients should discuss these risks with their healthcare provider.
How does Abrocitinib compare to other atopic dermatitis treatments?
Abrocitinib is a JAK inhibitor, a class of drugs that offers a different mechanism of action compared to topical corticosteroids or other systemic immunomodulators. Its selective JAK1 inhibition aims to reduce inflammation by targeting specific signaling pathways [1]. Other treatments for atopic dermatitis include topical therapies, other oral medications, and biologic drugs [4].
Can biosimilars be developed for Abrocitinib?
The development of biosimilars for complex biologic drugs is a lengthy process. For small molecule drugs like abrocitinib, the concept is more akin to generic versions. Once patents expire and regulatory exclusivities are no longer in effect, generic versions of abrocitinib may become available, potentially increasing access and reducing costs [3].
Sources:
[1] https://www.fda.gov/drugs/drug-approvals/abrocitinib-xeljanz
[2] https://patents.google.com/patent/US9035074B2/en
[3] https://drugpatentwatch.com/
[4] https://www.mayoclinic.org/diseases-conditions/atopic-dermatitis-eczema/diagnosis-treatment/drc-20353275